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Encapsualtion of pharmaceuticals inside nanoporous materials is of increasing interest due to their 
possible applications as new generation therapeutics, thernostic platforms or smart devices. 
Mesoporous silicas are leading materials to be used as nanohosts for pharmacueticals. Further 
development of new generation of nanoscale therapeutics requires complete understanding of the 
complex host–guest interactions of organic molecules confined in nanosized chambers at different 
length scales. In this context we present results showing control over formation and phase 
transition of nanosize crystals of model flexible pharmaceutical molecule tolbutamide confined 
inside 3.2 nm pores of the MCM-41 host. Using low loading levels (up to 30 wt. %) we were able 
to stabilise the drug in highly dynamic amorphous/disordered state or direct the crystallisation of 
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the drug into highly metastable nanocrystalline form V of tolbutamide (at loading levels of 40 and 
50 wt. %), providing first experimental evidence for crystallisation of pharmaceuticals inside the 
pores as narrow as 3.2 nm. 
Introduction  
Mesoporous silicas have attracted much interest in materials science due to unique features 
including synthetically controllable architecture of the pores and pore size diameter, large surface 
area and possible functionalisation of the silanol groups on the materials surface.1–5 Recently, 
mesoporous silica nanoparticles have gained increasing importance for pharmaceutical 
applications as intracellular drug delivery systems or novel diagnostic platforms.1,6–12 Controllable 
encapsulation and manipulation of the drug phase under nanoscale confinement make these 
materials interesting as nanoscale crystallisation chambers for polymorph screening, leading to 
discoveries of new crystalline phases or stabilization of metastable crystals.13,14  For example Ward 
and co-workers demonstrated formation of new polymorphs of pimelic acid, suberic acid and 
coumarin when confined inside CPG material (controlled pore glass) with pore sizes lower than 
23 nm.13,15 Selective crystallisation and stabilisation of metastable form of paracetamol (form III) 
was demonstrated by Beiner and co-workers inside the CPG with pore size (d) in the range from 
22 nm to 103 nm and stabilisation of amorphous drugs inside smaller pores (below 10 nm).16,17  
The investigation of structure and phase transitions of confined nanosize crystals using PXRD and 
DSC is far from trivial, due to a decrease of long range ordering in the materials, reflected in 
broadening of the PXRD peaks and decrease and broadening of the melting peak of confined 
crystals.15,17,18 Furthermore, simultaneous presence of molecules in different physical states and 
motional regimes inside the mesopores makes detailed characterisation of such complex 
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composites very challenging.18–20 Therefore, application of methods sensitive to the local 
environment of atoms (namely solid-state NMR) is of high importance for molecular-level 
understanding of crystallisation and phase transitions of pharmaceuticals.21–24  
Recently we have demonstrated controllable crystallisation and stabilisation of metastable 
indomethacine form V inside the 30 nm pores of MCF material (Mesoporous Cellular Foam).18 
Furthermore, we developed a 19F MAS NMR protocol to probe the local environment of confined 
flufenamic acid in situ and showed for the first time the simultaneous presence of confined 
molecules as nanocrystalline, amorphous and highly mobile species adsorbed at the silica surface 
during confined crystallisation.21 A recent study of Navrotsky and co-workers demonstrated 
crystallisation of the iodide salt of the rigid, spherical organic ion N,N,N-trimethyl-1-
adamantammonium (TMAAI, 321,3 g mol-1) within 12.8 nm pores of SBA-15 type silica and the 
coexistence of crystalline and amorphous species inside the pores using 13C MAS NMR and 
selectively labelled (13C) TMAAI.25 Furthermore, the authors indicated that a pore size of at least 
one unit cell and temperature below the (depressed) melting point can serve as sufficient indicators 
of the formation of confined nanocrystals.25 This is in agreement with the crystallisation of 
ibuprofen (206.3 g mol-1) confined within 11.6 nm pores of SBA-15 at 223 K reported by Azais et 
al.26   
Based on our previous findings18,21 and the recent report from Navrotsky’s group25, we have 
selected a small and flexible molecule (tolbutamide, 270.35 g mol-1) as a model to probe hypothesis 
that size and flexibility of organic molecules, together with high loading levels within the pores 
play an essential role in the successful crystallisation of pharmaceuticals inside porous hosts even 
with relatively narrow mesopores. Tolbutamide (TB) contains a rigid benzene ring and a highly 
mobile aliphatic chain with seven bonds that can rotate freely. The high flexibility of this structure 
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has led to a large number of TB polymorphs reported in the Cambridge Structural Database (7 
structures including a high Z’ form III).27–32 Due to its high flexibility, TB adopts different 
conformations in different crystal forms making it a representative example of conformational 
polymorphism.27 Furthermore, due to its low glass transition temperature (Tg = 277 K) and 
crystallisation during cooling of the molten drug it is a challenging material to be stabilised in its 
amorphous state.33–36 Using several complementary techniques (N2 adsorption, PXRD, DSC and 
solid-state NMR), we have demonstrated that TB can be encapsulated within the pores of MCM-
41 silica host with relatively narrow mesopores (diameter ca. 3.2 nm, much smaller than that for 
SBA-15, MCF or CPG silicas) using melt loading method. Through the gradual increase of the 
guest content we have achieved gradual filling of the pores and showed that the model drug can 
be successfully stabilised in it amorphous state at drug loadings up to 30 wt% or its crystallisation 
can be directed into metastable form V as confirmed using PXRD and solid-state NMR 
corroborated by DFT calculations. As previously reported by Nath et al., TB form V could only 
be obtained using crystallisation from acidified methanol and it is stable for only few hours at 
room temperature.29 In this work we demonstrate for the first time crystallisation of metastable TB 
form V inside the pores of MCM-41 (3.2 nm) silica scaffold and also report in-situ monitoring of 
its phase transition to TB form IH using solid-state NMR.  
Experimental Section 
Materials and Synthetic protocols 
Materials  
Tolbutamide, n-hexadecyltrimethylammonium bromide, ammonia, ethanol, tetraethyl 
orthosilicate (TEOS), methanol were all purchased from Sigma-Aldrich.  
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Synthesis of MCM-41  
Spherical, homogenous MCM-41 particles were synthesised according to the method previously 
published by Grün et al.37 In a typical synthesis, 2.5 g of n-hexadecyltrimethylammonium was 
dissolved in miliQ quality water (50 mL). A solution of ammonia (37% wt., 13.2 g) and ethanol 
(60 g) was mixed with the already prepared n-hexadecyltrimethylammonium solution. The 
solution was stirred for 15 minutes and 4.7 g of TEOS was added, resulting in a mixture of the 
following composition: 1 TEOS: 0.3 C16TMABr: 11 NH3: 144 H2O: 58 EtOH.  After stirring for 2 
hours, a precipitate was formed, filtered and washed using methanol and deionized water. The 
material was dried at 363 K overnight and calcined at 823 K for 5 hours.  
Drug loading 
TB (guest) was loaded into MCM-41 (host) using the melt loading method. Briefly, the drug and 
the host were mixed in a glass vial for 3 minutes using a spatula in host:guest ratios of 85:15, 
80:20, 75:25, 70:30, 60:40 and 50:50 (wt/wt). The obtained mixture of the powders was heated on 
a hot plate at 408 K, i.e. above the melting point of TB, and mixed with spatula for 5 minutes, 
ensuring that the drug can be adsorbed within the pores via capillary action. Once loaded, the 
samples were cooled to room temperature and stored within a desiccator. 
Characterisation methods 
Differential scanning calorimetry (DSC)  
DSC analysis was carried out using a Q2000 MTDSC instrument (TA Instruments, New Castle, 
DE, US). Crimped aluminium pans were used for all analyses. The sample weights ranged from 
2-4 mg for pure crystalline samples, and 8-10 mg for loaded drug:silica composites. A nitrogen 
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flow rate of 50 mL/min was used. The sample was heated with a heating rate of 5 K/min from 253 
to 408 K followed by cooling with 20 K/min to 253 K and subsequent heating with a heating rate 
of 5 K/min to 408 K. The data were analysed using the TA Instruments Universal Analysis 2000 
software (TA Instruments-Waters LLC). 
Thermogravimetric analysis (TGA)  
A TQ500 thermogravimetric analyser (TA Instruments, New Castle, DE, US) was used to 
determine the drug content within the composites. The samples (weight 5-10 mg) were heated at 
a rate of 5 K/minute from 298 K to 373 K to determine content of water adsorbed within the 
material and then further with heating rate of 30 K/minute to 873 K. The sample was kept at 873 
K for 15 minutes to ensure complete decomposition of the drug and then heated to 903 K. The 
samples were then cooled to room temperature. The analysis was performed in an inert gas 
atmosphere with 50 mL/min purge of N2. TA Instruments Universal Analysis 2000 software (TA 
Instruments-Waters LLC) was used to analyse the data. 
Powder x-ray diffraction (PXRD)  
ARL TM X’TRA Powder Diffractometer (Thermo Fisher Scientific Inc., Waltham, MA, US) was 
used with Cu Kα radiation with a wavelength of 0.15424 nm. The composites were analysed in 
the angular range 2θ from 6-36° and the step size of 0.01° using scanning rate of 6 seconds per 
step. The analysis was performed at room temperature. 
Scanning electron microscopy (SEM)  
The SEM images of the synthesized material were taken using a JSM 4900 LV microscope (JEOL 
Ltd, Japan) at 20 kV. Prior to the analysis the samples were sputtered with thin film of gold. 
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Nitrogen adsorption-desorption analysis  
Nitrogen adsorption-desorption isotherms were measured using a Nova 2200e Surface Area and 
Pore Size Analyzer (Quantachrome, Hook, UK) at 77 K.  All samples were outgassed under a high 
vacuum at 313 K for 12 h prior to the analysis to avoid any temperature driven recrystallization of 
the loaded drug. The BET specific surface area was calculated over a relative pressure range from 
0.05 to 0.20 assuming monolayer coverage and a molecular area of the nitrogen of 0.162 nm2.  The 
pore size distribution curves were calculated by applying the NLDFT method implemented in the 
NovaWin (ver. 11.03) software (Quantachrome Instruments) using spherical/cylindrical pore 
model and N2 adsorption on silica at 77 K.  
Nuclear magnetic resonance spectroscopy (NMR)  
All solid-state NMR spectra were acquired using a Bruker AVANCE III solid-state NMR 
spectrometer with a Larmor frequency of 400.23 MHz for 1H and 100.64 MHz for 13C. 1H-13C cross-
polarisation/magic angle spinning experiments (CP/MAS) were acquired using the RAMP CP 
pulse sequence. The MAS spinning rate was 10.0 kHz, the 1H π/2 pulse length was optimised to 
3.20 μs along with optimisation of the pulse delay to 10.0 s. SPINAL64 decoupling was used and 
the contact time (for CP) was set to 2.0 ms.  The number of scans changed from 1024 for crystalline 
phases and high loading composites (30-50%) to 6144 for materials loaded with TB at 
concentration of 15-25 %. TMS was used as a reference. 1H NMR spectra were acquired using 16 
scans and single π/2 pulse sequence without decoupling. The variable temperature (VT) 
experiments were performed in the temperature range from 293 to 373 K in 10 K steps. The 
temperature of the sample was stabilised for 5 min before spectra acquisition. The temperature 
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control was achieved using a Bruker BCU II chilling unit and a standard heater implemented in 
the probe.  
1H Solution-state NMR spectra of TB were recorded using Bruker Avance I spectrometer equipped 
with a triple resonance probe operating at 499.69 MHz for 1H. The obtained spectra corroborated 
by online spectra predictor38 and CASTEP calculations were used for 1H assignment. 
1H and 13C NMR chemical shift calculations using first principles. Computations were performed 
using the CASTEP code.39 Geometry optimisation was carried out with constrained cell parameters 
and positions of all heavy atoms using the PBE exchange-correlation functional40 with the addition 
of the Tkatchenko and Scheffler (TS) model41, a plane wave basis set cut-off energy of 1100 eV 
and ultrasoft pseudopotentials42.  
The NMR chemical shieldings were calculated using the gauge including projector augmented 
wave approach (GIPAW)43 and a cut-off energy of 1100 eV. The isotropic NMR shieldings 
computed with CASTEP were converted to chemical shifts using the following equation:  
δcalc= σref – σiso,  
where σiso is the isotropic chemical shielding generated from first-principles calculations and σref = 
169.5 ppm (for 13C) and 30.6 ppm (for 1H) as reported by Bradley et al.44 
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Results and discussion 
Effect of drug loading on the mesoscopic parameters of MCM-41 host 
 
Figure 1. Nitrogen adsorption/desorption isotherms (left) and pore size distribution (right) of 
MCM-41 host and TB loaded composites.  The isotherms are offset by 50 cm3/g. The adsorption 
step is presented in black and desorption step is presented in white points in the isotherms. 
Table 1. Drug content and structural parameters of MCM-41 host and loaded composites. 
Host-guest composite TB (g/g) Vtotal [cm3/g] dpore [Å] SBET [m2/g] 
MCM-41 N/A 0.66 32 1277 
MCM-TB 85-15 0.163 0.39 32 780 
MCM-TB 80-20 0.211 0.33 31 614 
MCM-TB 75-25 0.254 0.26 31 485 
MCM-TB 70-30 0.317 0.12 28 176 
MCM-TB 60-40 0.420 0.05 N/A 35 
MCM-TB 50-50 0.504 0.02 N/A 2 
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Synthesised submicrometer spherical particles of MCM-41 host with pore size diameter of ca. 3.2 
nm were loaded with tolbutamide using the melting method. Loaded composites analysed with 
nitrogen adsorption/desorption isotherms show a gradual decrease of the total pore volume and 
surface area with increasing drug content (Figure 1, Table 1). These results are corroborated by 
low angle PXRD, where gradual attenuation of the d[100] reflections is observed with increasing 
drug content (Figure 2). This may be attributed to a reduction in the X-ray scattering contrast 
between the silica walls and the pore filling material and not to a loss of crystallinity of the 
MCM-41 host.45 Thermogravimetric analysis of the drug-SiO2 composites confirmed that the 
expected drug content was achieved during loading and loading temperature was below the thermal 
degradation point of the drug (see ESI Figure S2). It is important to mention that water content of 
final composites was low and ca. 1-2 wt. % as determined by TGA. 
 
Figure 2. A. Low angle PXRD patterns of MCM-TB composites at different loading levels. B. 
SEM micrograph of MCM-41 particles. 
Formation of confined metastable form V of TB  
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Amorphous tolbutamide has low glass transition temperature (Tg = 277 K) and is included in the 
first class of glass forming agents based on the classification system implemented by Taylor et al.35 
Compounds in this class recrystallise during cooling from the undercooled melt state, regardless 
of cooling rate.35,36 Based on the results reported by Kawakami et al.36, supercooled TB recrystallises 
to form IV on cooling, with a further recrystallisation to form III observed during subsequent 
heating.  
 
Figure 3. A. PXRD patterns of MCM-TB composites at different drug loadings. The PXRD pattern 
of TB forms IL, IV and V were simulated using CSD ref codes: ZZZPUS1029, ZZZPUS0727 and 
ZZZPUS0446 and B. DSC thermograms of MCM-TB composites and TB form IL using the heat-
cool-heat cycle. 
Tolbutamide encapsulated inside the silica scaffolds using the melting method displayed a very 
different behavior compared to the bulk drug cooled from the melt. We found that TB remained 
amorphous at loading levels up to 30 wt. %, with crystallisation into the highly metastable TB 
form V occurring at higher drug loadings (40-50 wt. %), confirmed using a combination of PXRD, 
DSC and solid-state NMR. PXRD patterns (Figure 3A) show a broad ‘halo’ peak due to the 
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presence of amorphous MCM-TB composites at drug concentrations up to 30 wt. %. The small 
reflection at d = 8.39 Å observed for composites loaded with TB at 20 and 25 wt. % may indicate 
the confined guest is present as a mixture of amorphous and partially crystalline TB form V. The 
synthesized amorphous composites were stable during storage over at least a year. The 
stabilization of amorphous drug upon confinement in small pores is frequently observed 
phenomena for highly unstable amorphous pharmaceuticals.47 The PXRD patterns of the host 
loaded at 40 and 50 wt. % are in agreement with the simulated PXRD pattern of the highly unstable 
crystalline TB form V, superimposed on a ‘halo’ peak of amorphous silica walls and residual 
amorphous TB confined within the pores.  
The observed TB form V has only been formed previously through crystallisation from acidified 
methanol.29 The obtained TB form V encapsulated within the mesoporous silica host was stable for 
at least one month when stored in a desiccator over a silica gel at RT as compared to couple of 
hours reported by Nath et al.29 for bulk TB form V (See ESI Figure S5). DSC analysis (Figure 3B) 
of MCM-TB composites with drug content up to 30 wt. % does not show the melting peaks 
characteristic of TB polymorphs. The broad endotherm observed here may be related to continuous 
increase of mobility with increasing temperature and possible transition to liquid-like species for 
small amount of TB confined within the MCM-41 pores. This phenomenon was previously 
observed by Navrotsky et al. for confined TMAAI.25 It can also be related to evaporation of small 
content of water adsorbed at the surface of the silica. This hypothesis is corroborated by 
heat/cool/heat DSC cycle data (see ESI Figure S3), which show flattening of the DSC baseline 
during second heating, after removal of the adsorbed water in the first heating. This phenomenon 
is frequently observed for drug-silica composites and was discussed by Cordeiro et al. for naproxen 
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confined within MCM-41 and SBA-15 silica hosts.48 The detailed study of mobility of TB confined 
in porous silicas will be presented in a separate publication.  
At drug loadings of 40 and 50 wt. %, a broad melting endotherm of confined TB form V was 
observed at 339.9 K followed by recrystallisation and melting of TB form IH at 364.2 K. 
Furthermore, we were able to observe decrease of the glass transition temperature of confined TB 
in the MCM-TB 50-50 composite (Tg of confined TB = 269 K) during the second DSC heating 
run indicating differences in mobility of supercooled drug upon confinement as compared to bulk 
species. Due to the broadening and decrease of the melting point expected with confined crystalline 
material, TB form IH was identified only using variable temperature 13C solid-state NMR 
spectroscopy (Figure 5). This method enabled us to provide additional information on the 
supramolecular organisation of tolbutamide in the pores, and to monitor the phase transition of 
confined drug in situ.  
1H-13C CP/MAS NMR spectra of confined tolbutamide indicate the formation of amorphous drug 
at low drug content up to 30 wt. % (Figure 4D). The peak broadening is due to the presence of 
magnetically non-equivalent environments of the carbon atoms alongside increased distribution of 
possible orientations, typical of amorphous solids. At the higher drug content of 40 and 50 wt. %, 
much sharper 13C peaks of crystalline TB form V superimposed on broad peaks of residual 
amorphous TB are observed. This indicates the presence of crystalline TB form V confined within 
the MCM-41 host, in agreement with PXRD data.  
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Figure 4. A. TB structure with labelled atoms, B. Packing of TB form V viewed along b axis (CSD 
ref. ZZZPUS10)29, C. Experimental 13C chemical shift values for encapsulated TB form V derived 
from the spectra acquired at 293 K and an MAS rate of 10 kHz vs. calculated 13C chemical shifts 
using TB form V structure reported by Nath et al. (CSD ref. ZZZPUS1029), D. 1H-13C CP/MAS 
NMR spectra of MCM-TB composites at different drug loadings, E. 1H MAS solid-state NMR 
spectra of MCM-TB composites at different drug loadings (all spectra acquired at an MAS rate of 
10 kHz). 
The 1H-13C CP/MAS NMR spectrum of TB form V confined within MCM-41 host is in agreement 
with the 13C chemical shifts calculated with CASTEP, based on the ZZZPUS1029 structure reported 
recently in the CSD.49 Additionally, a decrease in the peak intensity of the amorphous TB (6144 
scans) as compared to crystalline TB (1024 scans) may indicate increased mobility of the confined 
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amorphous drug, resulting in the inefficient transfer of magnetisation during the cross-
polarisation.50 We recently observed similar phenomenon for flufenamic acid21 and indomethacin18 
confined within mesoporous silica materials with pore sizes from 3.2 to 30 nm and lactose51 
intercalated within sodium montmorillonite nanocomposites. These findings are in agreement with 
data presented by Azais et al.26,52 and Buntkowsky and co-workers.53 Furthermore, our data are 
consistent with the results of computational studies of encapsulation of ibuprofen or clotrimazole 
in MCM-41 silicas postulating the presence of a highly dynamic adsorbed layer of the drug at the 
surface of the pores.54,55   
1H MAS NMR spectra of rigid solids usually show very broad peaks due to the presence of strong 
homonuclear 1H-1H dipolar interactions. To partially overcome these interactions in 1H solid-state 
NMR, fast MAS (up to 120 kHz) and/or 1H-1H homonuclear decoupling sequences are used.56–58 In 
the case of confined TB at drug contents up to 30 wt. %, five different proton sites were identified, 
indicating that the confined drug is in a highly dynamic state. These sites were assigned to the 
protons of aromatic ring (H4, H7 and H3, H6) and to two CH3 groups (H1 and H12). The 
assignment was carried out based on both 1H solution NMR spectra of TB, and CASTEP 
calculations (see ESI). Further increase of the drug content within the material (40-50 wt. % drug 
loading) lead to crystallisation of TB inside the pores. This was confirmed by the broadening of 
the 1H peaks, consistent with the presence of enhanced 1H-1H dipolar interactions, which are 
expected for rigid crystalline solids (Figure 4E). 
In situ monitoring of phase transitions of TB under confinement via solid-state NMR. 
The investigation of phase transitions of confined solids is a considerable analytical challenge due 
to decrease and broadening of the melting peak in DSC and broadening of PXRD peaks for nano-
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size crystals.13,14,59 In such cases, full understanding of the phase transitions in confinement requires 
application of methods sensitive to the local environment of atoms, therefore solid-state NMR is 
ideal to probe both structure and dynamics. 
 
Figure 5 A. 1H-13C CP/MAS B. 1H MAS solid-state NMR spectra of MCM-TB 50-50 composite 
and TB form IH (acquired at 323 K) in the temperature range from 293K to 373K. Peaks are labelled 
according to the structure in Figure 4A. 
At temperatures up to 333 K there was no change observed in the spectra of the MCM-TB 50-50 
composite, which is in agreement with DSC analysis.  At 333 K peak splitting was detected, which 
indicated the presence of two crystalline phases. This agrees with DSC results, where the first 
transition onset was observed at ca. 339 K. With increasing temperature further (up to 343 K) 
recrystallisation was observed through growth of the peaks associated with form IH, resulting in 
only one phase being detected by 353 K, as the confined metastable TB form V underwent a phase 
transition to TB form IH. This transition was in agreement with the DSC data, which demonstrated 
that there is a narrow temperature range at which TB form IH can be present before it melts at 366 
K. When the temperature reached 373 K, the confined drug melted. This was confirmed firstly by 
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a loss of the CP efficiency observed as a substantial decrease of the peaks intensity in the 1H-13C 
CP/MAS spectrum (Figure 5A), and secondly by the significant narrowing of lines in the 1H 
spectrum at 373 K, due to an increased mobility (Figure 5B). When the material is cooled to 293 
K the 1H-13C CP/MAS NMR spectrum shows broad peaks characteristic of amorphous TB. 
The VT 1H MAS spectra of the MCM-TB 50-50 composite with confined TB form V showed a 
gradual narrowing of proton peaks H1, H3, H4, H6 and H7 with increasing temperature. The 
gradual narrowing of the peaks was attributed to increased dynamics of the aromatic ring of 
tolbutamide with increasing temperature. This is not unexpected as all TB polymorphs are 
stabilised through the rigid sulfonylurea bonding motif, hence the aromatic ring of tolbutamide 
may be in a different motional regime compared to the aliphatic part of the molecule. 
Conclusions 
We demonstrated that the drug content inside the pores is an important factor in directing formation 
of confined nanocrystals for very flexible TB guest species. The model drug TB can be stabilised 
in its amorphous state at drug loadings up to 30 wt. % or it can form confined nanocrystals of 
metastable form V inside the relatively narrow 3.2 nm mesopores of MCM-41 silica host. Using 
VT solid-state NMR spectroscopy, we were able to identify the phase transition from TB form V 
to TB form IH, which was difficult to monitor using thermal methods.  
ASSOCIATED CONTENT 
Supporting Information. Assignment of 1H solid-state NMR spectra of TB based 1H solution-
state NMR experiment and predicted chemical shifts values, heat-cool-heat cycles of DSC 
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experiments and 1H-13C CP/MAS spectra of MCM-TB 50-50 composite after 10 days and one 
month of storage are given in ESI.   
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